Drugs / Shuxuening injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06157502 | Jan 2024 → Dec 2025 overdue | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shuxuening injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06157502 ↗ |
| Known as | SXNI | “Shuxuening injection (SXNI), a multi-target cerebroprotectant, holds promise as adjuvant therapy to intravenous thrombolysis (IVT) in acute ischemic stroke (AIS)” PMID 41815809 ↗ Nov 2025 |
| Route | Intravenous | “intravenous drip once a day” NCT06157502 ↗ |